YOLFTbeta
DBV Technologies

DBV Technologies

DBVT · NASDAQ · Healthcare / Biotechnology

11.02USD-0.41 (-3.63%)

Price History

Full chart

Market Stats

Previous Close11.43
Open11.37
Day Range10.51 – 11.99
52-Week Range9.13 – 26.19
Volume278.93K
Market Cap729.04M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.34
Dividend Yield0.00%
Beta-0.23
50-Day Avg13.61
200-Day Avg18.08

About

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Daniel Tassé
  • Employees170
  • HeadquartersBAtiment IRO, Châtillon, France, 92320, USA
  • Websitehttps://www.dbv-technologies.com

Leadership

  • Mr. Daniel TasséCEO & Director · b. 1960
  • Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A.Chief Financial Officer · b. 1969
  • Dr. Pharis Mohideen M.D.Chief Medical Officer · b. 1965
  • Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C.Chief Operations Officer
  • Mr. Jonathan NeelyVP & Head of Investor Relations
  • Ms. Michele F. RobertsonChief Legal Officer
  • Mr. James BriggsChief Human Resources Officer · b. 1972
  • Mr. Kevin TrappChief Commercial Officer · b. 1967
  • Alan KerrSenior VP & Head of Global Regulatory Affairs
  • Mr. Pascal WotlingChief External Manufacturing & Supply Chain Officer

Financials

Income Statement

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue130.48K209.06K236.36K163.37K230.59K251.32K256.58K220.85K7.93M11.52M12.81M14.71M11.28M5.71M4.84M15.73M2.57M0
Growth (%)-+60.22%+13.06%-30.88%+41.14%+8.99%+2.09%-13.93%+3489.36%+45.31%+11.25%+14.77%-23.33%-49.38%-15.14%+224.69%-83.67%-100.00%
Cost of Revenue243.35K349.69K320.36K238.87K109.71K140.85K165.38K139.94K1.42M3.43M5.03M3.09M17.49M10.39M20.30M-4.50M6.81M17.67M
Gross Profit-113.00K-141.00K-84.00K-63.57K120.88K110.47K91.20K80.90K7.93M11.52M12.81M14.71M11.28M-4.68M4.84M15.73M-6.81M-17.67M
Gross Margin-86.60%-67.45%-35.54%-38.91%52.42%43.96%35.54%36.63%100.00%100.00%100.00%100.00%100.00%-82.04%100.00%100.00%-265.34%-
Operating Expense7.39M6.20M8.09M9.35M17.79M27.59M29.91M54.42M130.05M185.46M202.93M185.73M170.12M93.93M101.47M92.16M113.71M129.38M
Operating Income-7.51M-6.34M-8.17M-9.41M-17.67M-27.48M-29.82M-54.34M-122.13M-173.94M-190.12M-171.02M-158.84M-98.61M-96.63M-76.43M-120.53M-147.06M
Operating Margin-5753.37%-3033.14%-3456.97%-5760.44%-7664.19%-10932.76%-11622.20%-24603.46%-1540.62%-1509.99%-1483.57%-1162.79%-1408.67%-1727.65%-1994.86%-485.96%-4693.41%-
EBITDA-5.82M-4.75M-6.10M-9.11M-16.67M-29.56M-28.45M-47.51M-126.29M-176.90M-206.16M-168.43M-124.83M-91.16M-83.47M-63.27M-110.99M-139.32M
EBITDA Margin-4463.52%-2273.06%-2579.93%-5575.58%-7229.65%-11760.40%-11086.69%-21512.18%-1593.11%-1535.73%-1608.73%-1145.14%-1107.04%-1597.04%-1723.14%-402.28%-4321.91%-
Net Income-6.07M-4.98M-6.36M-9.38M-17.02M-26.59M-29.07M-48.52M-126.35M-177.20M-190.26M-172.01M-159.56M-97.81M-96.27M-72.73M-113.72M-146.95M
Net Income Margin-4651.29%-2382.60%-2689.51%-5744.52%-7382.74%-10579.03%-11327.94%-21969.51%-1593.88%-1538.29%-1484.65%-1169.51%-1415.00%-1713.54%-1987.49%-462.40%-4428.22%-
R&D4.48M4.56M6.49M8.65M15.21M23.98M27.43M36.85M82.90M126.25M123.50M112.24M101.61M70.34M75.54M60.22M89.90M116.68M
R&D as % of Total Revenue3436.54%2182.66%2744.51%5296.47%6595.20%9541.70%10689.54%16687.57%1045.84%1096.04%963.68%763.13%901.09%1232.24%1559.52%382.90%3500.85%-
Interest Expense48.18K42.78K48.82K55.21K33.34K33.14K125.25K159.62K17.65K3.99M479.76K377.93K724.00K690.00K427.00K-740.00K-
Interest Expense % of Total Revenue36.92%20.47%20.65%33.80%14.46%13.19%48.82%72.28%0.22%34.63%3.74%2.57%6.42%12.09%8.82%-28.82%-

Balance Sheet

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets---26.57M73.33M84.80M197.96M409.53M317.16M250.28M234.76M271.73M272.25M146.32M246.52M182.99M65.66M233.72M
Total Liabilities---6.79M6.49M10.71M15.74M25.30M49.26M67.40M68.98M78.54M66.75M47.29M52.06M42.80M38.27M64.95M
Total Equity---19.79M66.84M74.09M182.22M384.24M267.90M182.88M165.78M193.19M205.49M99.03M194.45M140.19M27.39M168.77M
Cash---19.49M65.43M72.27M180.86M385.79M282.93M194.08M167.81M193.25M196.35M77.30M209.19M141.37M32.46M194.17M
Total Debt---1.39M2.08M2.74M6.69M6.01M5.28M6.46M5.24M27.14M15.47M10.66M10.03M6.55M7.80M21.68M
Net Debt----18.10M-63.35M-69.52M-174.17M-379.78M-277.65M-187.62M-162.57M-166.12M-180.88M-66.64M-199.17M-134.81M-24.66M-172.48M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.36M-17.80M-24.31M-32.45M-31.93M-65.68M-160.91M-186.74M-148.35M-165.61M-108.24M-55.70M-79.65M-104.47M-121.18M
Investing Cash Flow-1.76M-629.23K-2.58M-1.73M-6.38M-9.16M-11.03M-11.81M-5.66M-2.87M-433.00K-100.00K-808.00K-757.00K-1.37M
Financing Cash Flow16.35M63.30M29.78M152.81M287.53M1.84M402.58K178.62M207.58M149.55M274.00K194.10M6.77M587.00K276.18M
Capital Expenditure1.21M616.73K2.15M1.53M5.38M9.05M10.62M6.49M5.60M2.76M918.00K754.00K677.00K2.34M533.64K
Free Cash Flow-11.57M-18.42M-26.46M-33.99M-37.31M-74.73M-171.53M-193.23M-153.94M-168.37M-109.16M-56.45M-80.33M-106.81M-121.18M
Dividends Paid---4.94M1.03M0000303.00K-----
FCF to OCF111.67%103.46%108.84%104.73%116.84%113.78%106.60%103.48%103.77%101.67%100.85%101.35%100.85%102.24%100.00%
Dividend Paid to FCF----14.53%-2.77%0.00%0.00%0.00%0.00%-0.18%-----

Earnings

Report DateMar 26, 2015Apr 29, 2015Jul 27, 2015Apr 28, 2016Jul 28, 2016Mar 21, 2017Apr 6, 2017Jul 30, 2017Mar 16, 2018Sep 6, 2018Mar 31, 2019Jul 31, 2019Sep 30, 2019Mar 22, 2020Jul 30, 2020Mar 11, 2021May 4, 2021Aug 1, 2021Oct 25, 2021Mar 8, 2022May 2, 2022Aug 1, 2022Nov 3, 2022Mar 2, 2023May 4, 2023Jul 31, 2023Oct 31, 2023Mar 7, 2024May 7, 2024Jul 30, 2024Nov 6, 2024Mar 5, 2025Apr 30, 2025Jul 29, 2025Oct 28, 2025Mar 27, 2026Apr 30, 2026Jul 16, 2026Oct 27, 2026
EPS Estimate-0.44-0.56-5.30-4.80-0.57-4.00-1.54-15.75-17.60-11.45-16.83-10.00-0.47-7.20-9.40-1.22-4.60-4.50-0.43-8.95-0.39-3.03-3.15-0.17-2.36-2.27-2.63-0.23-2.06-2.65-1.64-0.21-0.22-0.16-0.29-0.19-0.12-0.12-0.60
EPS Actual-0.79-0.18-4.20-4.00-2.03-2.200.00-12.40-9.40-9.20-9.40-8.10-0.42-10.40-7.60-2.95-4.08-2.61-3.10-3.79-0.27-3.41-3.69-0.44-2.00-2.36-1.61-0.06-5.20-1.57-1.49-0.21-0.23-0.27-0.21-0.20-0.09-0.60-
Surprise-79.55%68.55%20.75%16.67%-256.14%45.00%100.00%21.27%46.59%19.65%44.15%19.00%10.64%-44.44%19.15%-141.80%11.30%42.00%-620.93%57.65%30.77%-12.54%-17.14%-158.82%15.25%-3.96%38.78%74.74%-152.43%40.75%9.15%-1.24%-4.55%-68.75%27.59%-5.73%25.00%-400.00%-
TimingPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap729.04M
Enterprise Value603.74M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales144.77
Price / Book4.97
EPS-3.34
Book Value2.71
Revenue (TTM)5.04M
Gross Profit (TTM)5.04M
EBITDA-174.76M
Profit Margin0.00%
Operating Margin-7228.57%
Return on Equity-142.68%
Return on Assets-60.61%
Shares Outstanding62.85M
Shares Float34.94M
Beta-0.23
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 3 analystsTarget 39.08
  • Buy
    2
  • Sell
    1

Ownership Breakdown

Institutions
41.66%
Insiders
0.00%
Retail / Other
58.34%

Top Institutional Holders

  • MPM Oncology Impact Management LP
    3.67M7.78%
  • Siren, L.L.C.
    1.86M3.94%
  • Vivo Capital, LLC
    1.84M3.92%
  • Perceptive Advisors LLC
    1.65M3.51%
  • Baker Bros Advisors LP
    1.46M3.10%
  • Artisan Partners Limited Partnership
    1.37M2.91%
  • ADAR1 Capital Management LLC
    1.01M2.15%
  • Logos Global Management LP
    915.00K1.94%
  • Patient Square Capital LP
    909.47K1.93%
  • Octagon Capital Advisors LP
    574.20K1.22%
  • Ikarian Capital, LLC
    525.00K1.11%
  • Redmile Group, LLC
    410.44K0.87%
  • Duquesne Family Office LLC
    383.36K0.81%
  • Millennium Management LLC
    267.78K0.57%
  • Elmind Capital LP
    265.00K0.56%
  • Balyasny Asset Management LLC
    233.43K0.50%
  • Ameriprise Financial Inc
    231.42K0.49%
  • Yiheng Capital LLC
    170.14K0.36%

Top Fund Holders

  • Artisan International Small-Mid Investor
    840.25K1.78%
  • Fidelity Advisor Biotechnology I
    428.80K0.91%

Stock Splits

  • Jun 7, 20241:2